{"classes":[{"categories":[{"measurements":[{"comment":"NA indicates that upper and lower limits of CI were not estimable as there were no patients with CR or PR in that disease cohort.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"NA indicates that upper and lower limits of CI were not estimable as there were no patients with CR or PR in that disease cohort.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"ORR was defined as the percentage of patients with a confirmed BOR of CR or PR as determined by the investigator using RECIST v1.1. BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.","id":"OG000","title":"Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab"},{"description":"Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.","id":"OG001","title":"Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab"}],"paramType":"NUMBER","populationDescription":"The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.","reportingStatus":"POSTED","timeFrame":"Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 42 months","title":"Dose Escalation Phase: Objective Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of patients"}